細胞番号 : 細胞名
RCB3577 : Yamato-SS
update : 2024/08/14
|
| 細胞特性(Comment:英) | Human cell line derived from synovial sarcoma. |
| 細胞特性(日) | ヒト滑膜肉腫由来細胞株 |
| 細胞特性(寄託者記述:英) | |
| 細胞特性(寄託者記述:日) | |
| 使用条件(英) | In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Stem Cells 2010;28:1119-1131) designated by the DEPOSITOR is required. |
| 使用条件(日) | 利用者は、研究成果の公表にあたって寄託者の指定する文献 (Stem Cells 2010;28:1119-1131) を引用すること。 |
| 備考(英) | |
| 備考(日) | |
| 提供申込書類(英) |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
| 提供申込書類(日) |
依頼書C-0001.pdf
同意書(非営利学術目的)C-0003.pdf
同意書(営利目的)C-0003p.pdf
|
|
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
|
| 提供手数料 |
手数料とお支払いについてはこちらをご覧ください。 |
|
細胞基本情報
|
|
寄託者 |
Naka, Norifumi
|
| 樹立者 |
Naka, Norifumi
|
| 寄託日 |
2011
|
| 動物種 |
_human
< Mammals
|
| 属名 |
Homo
|
| 種名 |
sapiens
|
| 性別 |
Male
|
| 齢 |
30 years
|
| 採取組織 |
subcutaneous tissue of thigh
|
| 病名 |
Synovial sarcoma (Stage 4)
|
| 転移 |
Yes
|
| 転移巣 |
Lung
|
| 細胞分類 |
cancer
|
| 初代培養日 |
2006
|
|
細胞寿命 |
infinite
|
| 細胞形態 |
other
|
| Cellosaurus(Expasy) |
CVCL_6C44
|
|
細胞培養・検査情報
| |
寄託時情報 |
ロット情報 |
| 培地・試薬情報 |
培地・試薬一覧はこちらをご覧ください。 |
|
培養形態 |
|
Adherent cells
|
| 培地 |
|
DMEM (high glucose, without Sodium pyruvate) + 20% FBS
|
| 抗生物質 |
|
Free
|
|
継代方法 |
|
0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
|
|
継代密度 |
|
1 : 6 split
|
| 継代・培地交換頻度 |
|
Subculture : 1-2 times/week, Medium Renewal : 2 times/week
|
| 培養最適温度 |
|
37
℃
|
| 二酸化炭素濃度 |
|
5
%
|
| 凍結培地 |
|
Medium + 10% DMSO
|
| 凍結方法 |
|
Slow freezing
|
| マイコプラズマ/アコレプラズマ |
|
(-)
|
| 動物種PCR |
|
OK
|
| 個体識別検査 |
|
OK
|
|
寄託時情報
|
|
|
ロット情報
|
| D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
|
12
|
8,11
|
10,12
|
9,12
|
14,18
|
7,9
|
X,Y
|
8,11
|
10
|
|
| 画像情報 |
寄託時情報 | ロット情報 |
|
|
|
| 文献情報 |
Reference(英) |
10件
|
| Reference(日) |
0件
|
| 利用者成果(英) |
5件
|
| 利用者成果(日) |
0件
|
| Reference(英) |
|
22279
Sasagawa S, Kumai J, Wakamatsu T, Yui Y.
Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma
Cancer Innov
2024
3(2):e113
PubMed ID: 38946933
DOI: 10.1002/cai2.113
|
|
15489
Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T.
Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma
Cancers (Basel)
2021
13(8):1823
PubMed ID: 33920416
DOI: 10.3390/cancers13081823
|
|
15896
Yasuda N, Takenaka S, Nakai S, Nakai T, Yamada S, Imura Y, Outani H, Hamada K, Yoshikawa H, Naka N.
TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma
FEBS Open Bio
2020
10(5):767-779
PubMed ID: 32128992
DOI: 10.1002/2211-5463.12827
|
|
16158
Nakai S, Yamada S, Outani H, Nakai T, Yasuda N, Mae H, Imura Y, Wakamatsu T, Tamiya H, Tanaka T, Hamada K, Tani A, Myoui A, Araki N, Ueda T, Yoshikawa H, Takenaka S, Naka N.
Establishment of a novel human CIC-DUX 4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs
Sci Rep
2019
9(1):15812
PubMed ID: 31676869
DOI: 10.1038/s41598-019-52143-3
|
|
15823
Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.
Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
BMC Cancer
2017
17(1):334
PubMed ID: 28511645
DOI: 10.1186/s12885-017-3324-3
|
|
15501
Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N.
Trabectedin is a promising antitumour agent for synovial sarcoma
J Chemother
2016
28(5):417-24
PubMed ID: 27077926
DOI: 10.1080/1120009X.2015.1133013
|
|
15546
Imura Y, Nakai T, Yamada S, Outani H, Takenaka S, Hamada K, Araki N, Itoh K, Yoshikawa H, Naka N.
Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma
Cancer Sci
2016
107(12):1867-1876
PubMed ID: 27779808
DOI: 10.1111/cas.13092
|
|
16270
Toru Wakamatsu, Norifumi Naka, Satoru Sasagawa, Takaaki Tanaka, Satoshi Takenaka, Nobuhito Araki, Takafumi Ueda, Yasuko Nishizawa, Hideki Yoshikawa, Kazuyuki Itoh
Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma
Cancer Sci
2014
105(9):1124-34
PubMed ID: 24975049
DOI: 10.1111/cas.12469
|
|
15415
Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, Sasagawa S, Araki N, Ueda T, Itoh K, Myoui A, Yoshikawa H.
Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001
Cancer Lett
2014
347(1):114-22
PubMed ID: 24491407
DOI: 10.1016/j.canlet.2014.01.027
|
|
3639
Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K.
Synovial sarcoma is a stem cell malignancy.
Stem Cells.
2010
28(7):1119-31
PubMed ID: 20518020
DOI: 10.1002/stem.452
|
| 利用者成果(英) |
|
19686
Takeuchi M, Nishisho T, Toki S, Kawaguchi S, Tamaki S, Oya T, Uto Y, Katagiri T, Sairyo K.
Blue light induces apoptosis and autophagy by promoting ROS-mediated mitochondr
Cancer Med
2023
12(8):9668-9683
PubMed ID: 36722116
DOI: 10.1002/cam4.5664
|
|
20826
Murayama Y, Kasahara Y, Kubo N, Shin C, Imamura M, Oike N, Ariizumi T, Saitoh A, Baba M, Miyazaki T, Suzuki Y, Ling Y, Okuda S, Mihara K, Ogose A, Kawashima H, Imai C.
NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma.
Transl Oncol
2022
25:101521
PubMed ID: 35998437
DOI: 10.1016/j.tranon.2022.101521
|
|
20170
Yamada H, Takahashi M, Watanuki M, Watanabe M, Hiraide S, Saijo K, Komine K, Ishioka C.
lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.
Oncol Lett
2021
21(6):455
PubMed ID: 33907565
DOI: 10.3892/ol.2021.12716
|
|
20338
Murayama Y, Kawashima H, Kubo N, Shin C, Kasahara Y, Imamura M, Oike N, Ariizumi T, Saitoh A, Mihara K, Umezu H, Ogose A, Imai C.
Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma.
Transl Oncol
2021
14(12):101227
PubMed ID: 34555727
DOI: 10.1016/j.tranon.2021.101227
|
|
13326
Zhou F, Elzi DJ, Jayabal P, Ma X, Chiu YC, Chen Y, Blackman B, Weintraub ST, Houghton PJ, Shiio Y.
GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth.
Cell Rep
2020
PubMed ID: 33147457
DOI: 10.1016/j.celrep.2020.108332
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト
